down arrow

Nuvation Bio, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US67080N1019
USD
8.66
0.15 (1.76%)

Dec 16

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

8.148.80

52 Week

1.548.95
Valuation
Technical
Day's Volume

CASH

1.94 M

Shareholding (Mar 2025)

FII

11.48%

Held by 78 FIIs

DII

43.73%

Held by 58 DIIs

Promoter

13.74%

How big is Nuvation Bio, Inc.?

22-Jun-2025

As of Jun 18, Nuvation Bio, Inc. has a market capitalization of 581.85 million, categorizing it as a Micro Cap company, with net sales of 10.96 million and a net profit of -606.39 million over the latest four quarters.

Market Cap: As of Jun 18, Nuvation Bio, Inc. has a market capitalization of 581.85 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Nuvation Bio, Inc. reported net sales of 10.96 million and a net profit of -606.39 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 463.79 million and total assets of 540.63 million.

Read More

What does Nuvation Bio, Inc. do?

22-Jun-2025

Nuvation Bio, Inc. is a micro-cap biotechnology company focused on opportunities in the pharmaceuticals sector, with recent net sales of $3 million and a net loss of $53 million. The company has a market cap of $581.85 million and does not currently pay dividends.

Overview: <BR>Nuvation Bio, Inc. is a biotechnology company focused on identifying and acquiring opportunities within the pharmaceuticals and biotechnology sector, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -53 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 581.85 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.08 <BR>Return on Equity: -43.17% <BR>Price to Book: 1.39<BR><BR>Contact Details: <BR>Address: 357 Tehama Street, Floor 3, SAN FRANCISCO CA: 94103 <BR>Tel: 1 415 7543517 <BR>Fax: 1 302 6365454 <BR>Website: https://panacea.ecor1cap.com/

Read More

Is Nuvation Bio, Inc. overvalued or undervalued?

20-Sep-2025

As of August 5, 2024, Nuvation Bio, Inc. is considered risky due to overvaluation and poor financial metrics, including a Price to Book Value of 2.01, an EV to Sales ratio of 35.57, and a negative ROE of -43.17%, despite a year-to-date return of 19.17% that outperformed the S&P 500.

As of 5 August 2024, the valuation grade for Nuvation Bio, Inc. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its significant negative financial metrics, including a Price to Book Value of 2.01 and an EV to Sales ratio of 35.57, which are considerably high for a company in the pharmaceuticals and biotechnology sector. Additionally, the negative ROE of -43.17% further underscores the challenges the company faces.<BR><BR>In comparison to its peers, Nuvation Bio, Inc. has a worse EV to EBITDA ratio of -1.90 compared to uniQure NV's -6.6289, highlighting its relative inefficiency. The stock has experienced mixed performance, with a year-to-date return of 19.17%, outperforming the S&P 500's 12.22%, but it has significantly lagged over longer periods, with a 5-year return of -71.18% compared to the S&P 500's 96.61%. This performance suggests that while there may be short-term gains, the long-term outlook remains concerning.

Read More

Is Nuvation Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Nuvation Bio, Inc. shows a bullish technical trend with positive momentum indicators, having returned 19.17% year-to-date, outperforming the S&P 500, despite underperforming over longer periods.

As of 3 September 2025, the technical trend for Nuvation Bio, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. Daily moving averages also support a bullish stance. However, the monthly KST is mildly bearish, and the Dow Theory shows no trend on a weekly basis while being mildly bullish monthly. <BR><BR>In terms of performance, the stock has returned 19.17% year-to-date, outperforming the S&P 500's 12.22%, but has underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the current technical stance is bullish with moderate strength.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

The company has declared Negative results for the last 4 consecutive quarters

  • INTEREST(HY) At USD 0.47 MM has Grown at 259.85%
  • OPERATING CASH FLOW(Y) Lowest at USD -168.19 MM
  • OPERATING PROFIT(Q) Lowest at USD -63.23 MM
2

Risky - Negative EBITDA

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,198 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.09

stock-summary
Return on Equity

-54.17%

stock-summary
Price to Book

3.21

Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Jun 2025)
Net Profit:
-59 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
164.83%
0%
164.83%
6 Months
365.59%
0%
365.59%
1 Year
221.93%
0%
221.93%
2 Years
514.18%
0%
514.18%
3 Years
389.27%
0%
389.27%
4 Years
-8.84%
0%
-8.84%
5 Years
-17.52%
0%
-17.52%

Nuvation Bio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Nuvation Bio Hits New 52-Week High of $5.55, Up 81.38%

Nuvation Bio Hits New 52-Week High of $5.55, Up 81.38%

Nuvation Bio, Inc. has achieved a new 52-week high of USD 5.55, marking an 81.38% increase over the past year. With a market capitalization of USD 1,198 million, the company faces challenges, including a negative return on equity and a notable debt-to-equity ratio, while navigating the competitive biotechnology sector.

Read More
Nuvation Bio Hits Day High with 10.48% Surge, Showcases Strong Intraday Performance

Nuvation Bio Hits Day High with 10.48% Surge, Showcases Strong Intraday Performance

Nuvation Bio, Inc. has seen notable stock performance, with significant increases over various time frames, including a 110.87% return over the past year. Despite facing challenges such as negative results in recent quarters and declining profits, the company's market capitalization stands at approximately USD 1,198 million.

Read More
Nuvation Bio Hits New 52-Week High of $4.87, Up 67%

Nuvation Bio Hits New 52-Week High of $4.87, Up 67%

Nuvation Bio, Inc. has achieved a new 52-week high, reflecting a strong one-year performance that significantly outpaces the S&P 500. With a market capitalization of USD 1,198 million, the company faces challenges, including negative return on equity and a high debt-to-equity ratio, while pursuing a growth-focused strategy.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
97.97%
EBIT Growth (5y)
-232.77%
EBIT to Interest (avg)
-104.57
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.08
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
76.02%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.01
EV to EBIT
-1.89
EV to EBITDA
-1.90
EV to Capital Employed
-11.25
EV to Sales
35.57
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-43.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 41 Schemes (31.02%)

Foreign Institutions

Held by 78 Foreign Institutions (11.48%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 242.86% vs 0.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 87.24% vs -2,145.15% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.80",
          "val2": "1.40",
          "chgp": "242.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-63.20",
          "val2": "-45.10",
          "chgp": "-40.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.10",
          "chgp": "300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.50",
          "val2": "-423.90",
          "chgp": "100.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-59.00",
          "val2": "-462.50",
          "chgp": "87.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,157.30%",
          "val2": "-31,578.40%",
          "chgp": "1,842.11%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -649.21% vs 27.26% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-166.90",
          "val2": "-99.60",
          "chgp": "-67.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-426.00",
          "val2": "0.50",
          "chgp": "-85,300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-567.90",
          "val2": "-75.80",
          "chgp": "-649.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-21,282.50%",
          "val2": "0.00%",
          "chgp": "-2,128.25%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
4.80
1.40
242.86%
Operating Profit (PBDIT) excl Other Income
-63.20
-45.10
-40.13%
Interest
0.40
0.10
300.00%
Exceptional Items
0.50
-423.90
100.12%
Consolidate Net Profit
-59.00
-462.50
87.24%
Operating Profit Margin (Excl OI)
-13,157.30%
-31,578.40%
1,842.11%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 242.86% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 87.24% vs -2,145.15% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
7.90
0.00
Operating Profit (PBDIT) excl Other Income
-166.90
-99.60
-67.57%
Interest
0.30
0.00
Exceptional Items
-426.00
0.50
-85,300.00%
Consolidate Net Profit
-567.90
-75.80
-649.21%
Operating Profit Margin (Excl OI)
-21,282.50%
0.00%
-2,128.25%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -649.21% vs 27.26% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Nuvation Bio, Inc. stock-summary
stock-summary
Nuvation Bio, Inc.
Pharmaceuticals & Biotechnology
Panacea Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company is focused on identifying and acquiring opportunity within the biotechnology sector.
Company Coordinates stock-summary
Company Details
357 Tehama Street, Floor 3 , SAN FRANCISCO CA : 94103
stock-summary
Tel: 1 415 7543517
stock-summary
https://panacea.ecor1cap.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."